Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors.

ABSTRACT:

Background

Cannabis (CAN) use has risen significantly over the last few decades. CAN has potent immunosuppressive properties, which could antagonize the effect of immunotherapy (IO). The impact of CAN use on clinical cancer outcomes remains unclear.

Objectives

In this study, we evaluated the clinical effect of CAN use on clinical outcomes among patients with solid malignancies receiving IO.

Design

This is a retrospective cohort study of all patients with solid malignancies receiving IO between August 2014 and August 2018.

Methods

Patients were stratified based on CAN use to CAN users and CAN non-users. The primary outcome was overall survival (OS), and the secondary outcomes were progression-free survival (PFS) and disease control rate (DCR). Univariable and mu

SUBMITTER: Hadid T 

PROVIDER: S-EPMC11683815 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature